DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
Trusted Resources: News & Events
Latest announcements and gatherings
bluebird bio said today it has acquired a manufacturing facility in Durham, NC, from an undisclosed seller for $11.5 million, with the goal of producing lentiviral vectors for the company’s cell and gene therapies.
Those therapies, bluebird said, include the cerebral adrenoleukodystrophy treatment Lenti-D, as well as LentiGlobin for transfusion-dependent β-thalassemia and severe sickle cell disease and multiple myeloma treatments bb2121 and bb21217.
bluebird said the acquisition was part of a “significant” investment in manufacturing infrastructure that includes expanding in-house expertise, creating an extensive manufacturing network, and increasing manufacturing capacity.
news & eventsKids Who Need Sickle Cell Meds Don’t Always Get ThemLess than a fifth of U.S. children with ...
news & eventsNovartis acquires US pharma research firm Selexys PharmaceuticalsSwiss-based pharmaceuticals giant Novart...
education & researchPatient Reported Outcomes and Adherence to Hydroxyurea in Adolescents and Young Adults With Sickle Cell Disease: A F...Background: SCD-related complications r...
education & researchTranscutaneous electrical nerve stimulation (TENS) for pain management in sickle cell diseaseAs defined by the American Physical Ther...
news & events1st Patients to Get CRISPR Gene-Editing Treatment Continue to ThriveThe last thing a lot of people want to d...
news & eventsSpectra Optia Device Save Way to Treat Sickle Cell While Using Less Blood Cell Packs, Study FindsThe blood-separation device Spectra Opti...
news & eventsBioverativ and Bicycle Therapeutics Enter into Strategic Research Collaboration to Develop Therapies for Hemophilia ...Bioverativ Inc. (NASDAQ: BIVV), a global...
send a message
Don’t forget to join the oneSCDvoice community!
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.